Cancer Gene Therapy - Issue - nature.com science feeds Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer. http://www.nature.com/cgt/current_issue/ Nature Publishing Group en Copyright © Nature Publishing Group Cancer Gene Therapy 0929-1903 Copyright © Nature Publishing Group permissions@nature.com Cancer Gene Therapy http://www.nature.com/aj/images/logos_b_o_w/cgt.gif http://www.nature.com/cgt/ Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development http://feeds.nature.com/~r/cgt/rss/current/~3/LuVTwRcHT08/cgt.2009.53 Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development

Cancer Gene Therapy 16, 807 (November 2009). doi:10.1038/cgt.2009.53

Authors: D D Rao, N Senzer, M A Cleary & J Nemunaitis

]]> Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development D D Rao N Senzer M A Cleary J Nemunaitis doi:10.1038/cgt.2009.53 Cancer Gene Therapy 16, 807 (November 2009) 2009-10-16 Cancer Gene Therapy August 28, 2009 10.1038/cgt.2009.53 http://dx.doi.org/10.1038/cgt.2009.53 16 11 807 809 http://dx.doi.org/10.1038/cgt.2009.53 RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses http://feeds.nature.com/~r/cgt/rss/current/~3/v4GyOsOLBdk/cgt.2009.29 RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses

Cancer Gene Therapy 16, 810 (November 2009). doi:10.1038/cgt.2009.29

Authors: M Shiina, M D Lacher, C Christian & W M Korn

]]> RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses M Shiina M D Lacher C Christian W M Korn doi:10.1038/cgt.2009.29 Cancer Gene Therapy 16, 810 (November 2009) 2009-10-16 Cancer Gene Therapy May 1, 2009 10.1038/cgt.2009.29 http://dx.doi.org/10.1038/cgt.2009.29 16 11 810 819 http://dx.doi.org/10.1038/cgt.2009.29 Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells http://feeds.nature.com/~r/cgt/rss/current/~3/6Mn82boGvtU/cgt.2009.28 Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells

Cancer Gene Therapy 16, 820 (November 2009). doi:10.1038/cgt.2009.28

Authors: K-x Zhang, M Moussavi, C Kim, E Chow, I S Chen, L Fazli, W Jia & P S Rennie

]]> Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells K-x Zhang M Moussavi C Kim E Chow I S Chen L Fazli W Jia P S Rennie doi:10.1038/cgt.2009.28 Cancer Gene Therapy 16, 820 (November 2009) 2009-10-16 Cancer Gene Therapy April 17, 2009 10.1038/cgt.2009.28 http://dx.doi.org/10.1038/cgt.2009.28 16 11 820 831 http://dx.doi.org/10.1038/cgt.2009.28 Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status http://feeds.nature.com/~r/cgt/rss/current/~3/OpDD27ojhBs/cgt.2009.21 Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status

Cancer Gene Therapy 16, 832 (November 2009). doi:10.1038/cgt.2009.21

Authors: G Ma, K Kawamura, Q Li, N Suzuki, M Liang, M Namba, H Shimada & M Tagawa

]]> Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status G Ma K Kawamura Q Li N Suzuki M Liang M Namba H Shimada M Tagawa doi:10.1038/cgt.2009.21 Cancer Gene Therapy 16, 832 (November 2009) 2009-10-16 Cancer Gene Therapy April 10, 2009 10.1038/cgt.2009.21 http://dx.doi.org/10.1038/cgt.2009.21 16 11 832 840 http://dx.doi.org/10.1038/cgt.2009.21 Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer http://feeds.nature.com/~r/cgt/rss/current/~3/u_S82hdP8zU/cgt.2009.32 Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer

Cancer Gene Therapy 16, 841 (November 2009). doi:10.1038/cgt.2009.32

Authors: S R Murugesan, C R King, R Osborn, W R Fairweather, E M O'Reilly, M O Thornton & L L Wei

]]> Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer S R Murugesan C R King R Osborn W R Fairweather E M O'Reilly M O Thornton L L Wei doi:10.1038/cgt.2009.32 Cancer Gene Therapy 16, 841 (November 2009) 2009-10-16 Cancer Gene Therapy May 15, 2009 10.1038/cgt.2009.32 http://dx.doi.org/10.1038/cgt.2009.32 16 11 841 847 http://dx.doi.org/10.1038/cgt.2009.32 Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas http://feeds.nature.com/~r/cgt/rss/current/~3/bfqqWUfLuYc/cgt.2009.31 Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

Cancer Gene Therapy 16, 848 (November 2009). doi:10.1038/cgt.2009.31

Authors: L Vardouli, C Lindqvist, K Vlahou, A S I Loskog & A G Eliopoulos

]]> Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas L Vardouli C Lindqvist K Vlahou A S I Loskog A G Eliopoulos doi:10.1038/cgt.2009.31 Cancer Gene Therapy 16, 848 (November 2009) 2009-10-16 Cancer Gene Therapy May 22, 2009 10.1038/cgt.2009.31 http://dx.doi.org/10.1038/cgt.2009.31 16 11 848 860 http://dx.doi.org/10.1038/cgt.2009.31 Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy http://feeds.nature.com/~r/cgt/rss/current/~3/0Tiw8gxDB1w/cgt.2009.30 Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy

Cancer Gene Therapy 16, 861 (November 2009). doi:10.1038/cgt.2009.30

Authors: X Liu, J Wu, S Zhang, C Li & Q Huang

]]> Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy X Liu J Wu S Zhang C Li Q Huang doi:10.1038/cgt.2009.30 Cancer Gene Therapy 16, 861 (November 2009) 2009-10-16 Cancer Gene Therapy May 22, 2009 10.1038/cgt.2009.30 http://dx.doi.org/10.1038/cgt.2009.30 16 11 861 872 http://dx.doi.org/10.1038/cgt.2009.30